Evidence map›Paper›PMID 41619120›Full record

ArticleClinical journal of gastroenterology2026

Long-term survival following chemoradiotherapy for postoperative recurrence of hilar cholangiocarcinoma.

Kazuki Asakura, Takahiro Einama, Kazuki Kobayashi, Hanae Shinada, Naoto Yonamine, Takazumi Tsunenari, Mikiya Takao, Saburo Matsubara, Kazuyuki Oyama, Yoji Kishi

Abstract readCase Reports
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kazuki Asakura *Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Takahiro Einama *Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan. einama0722@ndmc.ac.jp.ORCID http://orcid.org/0000-0002-4434-0803
Kazuki KobayashiDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Hanae ShinadaDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Naoto YonamineDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Takazumi TsunenariDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Mikiya TakaoDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Saburo MatsubaraDepartment of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan.
Kazuyuki OyamaDepartment of Radiology, Shin-Yamanote Hospital, 3-6-1 Suwacho, Higashimurayama, Tokyo, 189-0021, Japan.
Yoji KishiDepartment of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard treatment for metastatic biliary tract cancer is systemic chemotherapy, not local therapy, such as surgery or radiation therapy. This is because long-term survival is not expected with local therapy. We present the case of a 49-year-old man who underwent extended right hepatectomy with extrahepatic bile duct resection for hilar cholangiocarcinoma. Postoperative adjuvant chemotherapy with oral S-1 for six months was completed. At 20 months post-operation, para-aortic lymphadenopathy was detected, and endoscopic ultrasound-guided biopsy confirmed lymph node recurrence. Gemcitabine and cisplatin were administered for six months, resulting in partial tumor regression. As no other lesions were identified, radiotherapy with a total dose of 55 Gy in 22 fractions was performed. At 37 months following the completion of radiotherapy, the patient remained disease-free based on imaging. This case suggests that the addition of local radiotherapy to systemic chemotherapy may be beneficial for patients with oligometastatic recurrence of hilar cholangiocarcinoma.

Indexed as

Bile Duct NeoplasmsBile Ducts, IntrahepaticChemoradiotherapyCholangiocarcinomaKlatskin TumorNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineDrug CombinationsGemcitabineHepatectomyHumansLymphatic MetastasisMaleMiddle AgedCisplatinDeoxycytidineDrug CombinationsGemcitabineOxonic AcidS 1 (combination)TegafurChemoradiotherapyCholangiocarcinomaOligometastasisRecurrence

Identifiers

PMID41619120
PMCPMC13048948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.